- Home
- NCDL vs PHAR Comparison
NCDL vs PHAR Comparison
Compare NCDL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- PHAR
- Stock Information
- Founded
- NCDL 2019
- PHAR 1988
- Country
- NCDL United States
- PHAR Netherlands
- Employees
- NCDL N/A
- PHAR N/A
- Industry
- NCDL
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NCDL
- PHAR Health Care
- Exchange
- NCDL NYSE
- PHAR Nasdaq
- Market Cap
- NCDL 770.8M
- PHAR 718.1M
- IPO Year
- NCDL N/A
- PHAR N/A
- Fundamental
- Price
- NCDL $16.04
- PHAR $11.24
- Analyst Decision
- NCDL Hold
- PHAR Strong Buy
- Analyst Count
- NCDL 3
- PHAR 3
- Target Price
- NCDL $15.75
- PHAR $30.00
- AVG Volume (30 Days)
- NCDL 221.6K
- PHAR 3.1K
- Earning Date
- NCDL 05-08-2025
- PHAR 05-08-2025
- Dividend Yield
- NCDL 11.08%
- PHAR N/A
- EPS Growth
- NCDL N/A
- PHAR N/A
- EPS
- NCDL N/A
- PHAR N/A
- Revenue
- NCDL N/A
- PHAR $320,708,000.00
- Revenue This Year
- NCDL N/A
- PHAR $13.31
- Revenue Next Year
- NCDL N/A
- PHAR $7.68
- P/E Ratio
- NCDL N/A
- PHAR N/A
- Revenue Growth
- NCDL N/A
- PHAR 24.13
- 52 Week Low
- NCDL $14.21
- PHAR $6.65
- 52 Week High
- NCDL $18.05
- PHAR $11.07
- Technical
- Relative Strength Index (RSI)
- NCDL 58.63
- PHAR 69.87
- Support Level
- NCDL $15.43
- PHAR $10.02
- Resistance Level
- NCDL $16.41
- PHAR $10.89
- Average True Range (ATR)
- NCDL 0.24
- PHAR 0.23
- MACD
- NCDL 0.09
- PHAR 0.11
- Stochastic Oscillator
- NCDL 84.73
- PHAR 100.00
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.